Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma
Malignant Evaluation and Clinical Prognostic Values of m6A RNA Methylation Regulators in Glioblastoma
复制标题
m6A RNA 甲基化调节因子在胶质母细胞瘤中的恶性评估和临床预后价值
DOI：
10.3389/fonc.2020.00208
复制
发表时间：
2020-03-09
影响因子：
4.7
通讯作者：
Chen, Lei
中科院分区：
文献类型：
--
作者：
Du, Jianyang;Hou, Kuiyuan;Chen, Lei
n6 -甲基腺苷（m6A） RNA甲基化是最常见的mRNA修饰形式，受m6A RNA甲基化调节剂（“书写器”、“擦除器”和“读取器”）的调控，据报道与恶性肿瘤的进展有关。然而，其在胶质母细胞瘤（GBM）中的作用尚不清楚。本研究旨在确定m6A RNA甲基化调节因子在GBM中的表达、潜在功能和预后价值。在这里，我们发现13个中心m6A RNA甲基化调节因子与GBM的临床和分子表型密切相关。利用共识聚类分析，我们获得了两类GBM样本，并发现了m6A甲基化调节因子和特异性靶向恶性过程的化合物的恶性相关过程。此外，我们还获得了GBM预后不良的基因列表。最后，我们获得了三个选定的m6A RNA甲基化调节因子的风险基因特征，这使我们能够扩展深入研究并将GBM患者的OS分为高风险和低风险亚组。值得注意的是，这种风险基因特征可以作为独立的预后标志物和准确的临床病理参数预测因子。总之，m6A RNA甲基化调节因子是GBM恶性进展的一种重要参与者，在GBM的预后分层和治疗策略中具有关键潜力。
N6-methyladenosine (m6A) RNA methylation, the most common form of mRNA modification and regulated by the m6A RNA methylation regulators ("writers," "erasers," and "readers"), has been reported to be associated with the progression of the malignant tumor. However, its role in glioblastoma (GBM) has been poorly known. This study aimed to identify the expression, potential functions, and prognostic values of m6A RNA methylation regulators in GBM. Here, we revealed that the 13 central m6A RNA methylation regulators were firmly related to the clinical and molecular phenotype of GBM. Taking advantage of consensus cluster analysis, we obtained two categories of GBM samples and found malignancy-related processes of m6A methylation regulators and compounds that specifically targeted the malignant processes. Besides, we also obtained a list of genes with poor prognosis in GBM. Finally, we derived a risk-gene signature with three selected m6A RNA methylation regulators, which allowed us to extend the in-depth study and dichotomized the OS of patients with GBM into high- and low-risk subgroups. Notably, this risk-gene signature could be used as independent prognostic markers and accurate clinicopathological parameter predictors. In conclusion, m6A RNA methylation regulators are a type of vital participant in the malignant progression of GBM, with a critical potential in the prognostic stratification and treatment strategies of GBM.